首页> 美国卫生研究院文献>Springer Open Choice >MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

【2h】

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

机译：MET靶向抗体（emibetuzumab）和激酶抑制剂（merestinib）作为单一药物或在带有MET外显子14跳跃的癌症模型中组合使用

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 Springer Open Choice
作者
S. Betty Yan; Suzane L. Um; Victoria L. Peek; Jennifer R. Stephens; Wei Zeng; Bruce W. Konicek; Ling Liu; Jason R. Manro; Volker Wacheck; Richard A. Walgren;
展开▼
作者单位

展开▼
年(卷),期 -1(36),4
年度 -1
页码 536–544
总页数 9
原文格式 PDF
正文语种
中图分类外科学;
关键词
Merestinib Emibetuzumab MET exon 14 skipping MET kinase inhibitor MET antibody LY2801653 LY2875358;

机译：Merestinib;Emibetuzumab;MET外显子14跳过;MET激酶抑制剂;MET抗体;LY2801653;LY2875358;

相似文献

外文文献
中文文献
专利

1. MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping [J] . Yan S. Betty, Um Suzane L., Peek Victoria L., Investigational new drugs. . 2018,第4期

机译：靶向抗体（Emibetuzumab）和激酶抑制剂（Metestinib）作为单一剂或组合在癌症模型中遇到外显子14跳跃
2. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer [J] . Journal of international management . 2020,第2期

机译：RAS-MAPK途径限制响应在遇到突变阳性肺癌患者中抑制抑制剂治疗的共同发生改变
3. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer [J] . Rotow Julia K., Gui Philippe, Wu Wei, Clinical cancer research: an official journal of the American Association for Cancer Research . 2020,第2期

机译：RAS-MAPK途径限制响应在遇到突变阳性肺癌患者中抑制抑制剂治疗的共同发生改变
4. IN SILICO HIT IDENTIFICATION,DRUG REPURPOSING,PHARMACOKINETIC AND TOXICITY PREDICTION OF C-MET KINASE INHIBITORS FOR CANCER THERAPY [C] . Pretisha Flora Cutinho, Venkataramana C.H.S., Suma B.V. Conference on Drug Design and Discovery Technologies . 2020

机译：在Silico HIS鉴定，药物重新扫描，药代动力学和癌症治疗中C-Met激酶抑制剂的毒性预测
5. Enhancing the Therapeutic Effects of Low Doses of Ionizing Radiation in Non-Small Cell Lung Cancers Using a Combination of PARP Inhibitors and DNA Demethylating Agents. [D] . Biondi, Christopher Anthony. 2016

机译：使用PARP抑制剂和DNA去甲基化剂的组合增强非小细胞肺癌低剂量电离辐射的治疗效果。
6. A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations [O] . Mariacarmela Santarpia, Marco Massafra, Vittorio Gebbia, 2021

机译：遇到外显子14跳闸突变的非小细胞肺癌患者抑制剂的叙事综述
7. MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping [O] . S. Betty Yan, Suzane L. Um, Victoria L. Peek, 2017

机译：靶向抗体（Emibetuzumab）和激酶抑制剂（Metestinib）作为单一剂或组合在癌症模型中遇到外显子14跳跃

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

著录项

引文网络

相似文献

相关主题

期刊订阅